2026/06/22 by Tércio Genzini, Keli Camila Vidal GROCHOSKI, Fernando Kruglensky Lerner +6 · 1 voice
Medicine · #Cholangiocarcinoma and Gallbladder Cancer Studies #Hepatocellular Carcinoma Treatment and Prognosis #Multiple and Secondary Primary Cancers
paper · doi:10.53855/bjt.v29i1.765_eng
openalex publication_date 2026/06/22 · openalex created_date 2026/06/24 · openalex updated_date 2026/07/21
Colorectal cancer (CRC) is on the rise and is already the second most common cancer in both men and women. Approximately 50% of CRC patients develop liver metastases (LM), and in about 35% of these, the lesions are confined to the liver. Unfortunately, only 20 to 40% of patients with CRC with LM (CRLM) have resectable disease, leaving the remainder with a poor prognosis, with 5-year survival rates of around 10%, despite advanced multimodal, systemic, and locoregional treatments. Since the 1980s, liver transplants have been performed to treat patients with unresectable CRLM. Poor survival rates, only slightly higher than with systemic chemotherapy, were observed at that time. With the publications from the Oslo group starting in 2013 and the establishment of selection criteria and immunosuppression strategies, significant life gains in survival have been achieved, leading to multicenter studies that are confirming the Norwegian findings and consolidating liver transplantation as a treatment alternative for selected patients with unresectable CRLM. This study presents a systematic review of published articles involving TF in CRLM, including case reports, case series, multicenter studies, and reviews on the subject, aiming to show the development, initial cases in various centers, and the current state of this important treatment alternative.